5-HYDROXITRYPTOPHAN DIETARY SUPPLEMENTATION IN POST-TRAUMATIC STRESS SYNDROME
RADU CIPRIAN ŢINCU 1,2, ADRIAN SILUAN IVAN 1, CRISTIAN COBILINSCHI 1,2, IULIA FLORENTINA ŢINCU 1,3*, RADU ALEXANDRU MACOVEI 1,2
1“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania 2Clinical Emergency Hospital, Bucharest, Romania
3“Dr. Victor Gomoiu” Clinical Children Hospital, Bucharest, Romania
Download Full Article PDF
Major depressive disorder (MDD) is a common psychological long-term consequence of patients that have been treated in intensive care units together with anxiety disorders (AD) and posttraumatic stress disorder (PTSD). This study aimed to investigate the effect of 5-hydroxytryptophan administration on serotonin levels in critically ill patients and the prevalence of psychiatric disorders in our patients. A randomized controlled trial was conducted in the Anaesthesia and Intensive Care Unit, Clinical Emergency Hospital Bucharest, Romania, on patients admitted for severe non-surgical illness aged from 18 to 55 years. Thirty subjects were recruited and randomized through sealed envelopes with a concealed 1:1 allocation to either treated or control group: Group 1 - placebo (control group) and Group 2 (5-TRP group) - treated with 300 mg of 5-hydroxytryptophan twice daily. After 7 days, Group 2 had higher levels of serum serotonin (230.06 ± 34.96 μg/L) in comparison to the control group (181.20 ± 38.87 μg/L; p < 0.001). The incidence of depression was 24.49% in Group 2 and 42.17% in Group 1 (p < 0.005) after 30 days of observation. Our results suggest that due to his role as an immediate precursor, 5-hydroxytryptophan increases the plasma level of serotonin, with a beneficial effect on anxiety and depression of the treated patients.
